Preoperative chemotherapy for soft tissue sarcomas of the extremities: The experience at the University of California, Los Angeles

  • C. Jay Engel
  • Frederick R. Eilber
  • Gerald Rosen
  • Michael T. Selch
  • Yao-Shi Fu
Part of the Cancer Treatment and Research book series (CTAR, volume 67)


The traditional approach to extremity sarcomas was surgical excision. This was associated with a local failure rate of approximately 95% [1], as tumors were simply ‘shelled out’ of their pseudocapsule. More radical muscle group and compartment excisions were then performed that reduced the local failure to approximately 40% [2]. Even with amputation, local failure was approximately 35%. Without effective additional therapy to control microscopic residual disease, radical surgery alone resulted in both poor functional results and high recurrence rates.


Soft Tissue Sarcoma Preoperative Chemotherapy Limb Salvage Soft Tissue Sarcoma Microscopic Residual Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bowden L, Booher RJ: The principles and techniques of resection of soft parts for sarcoma. Surgery 44:963–967, 1958.PubMedGoogle Scholar
  2. 2.
    Shiu MH, Castrol EB, Hadju SI, Fortner JG: Surgical treatment of 297 soft tissue sarcomas of the lower extremity. Ann Surg 182:597–602, 1975.PubMedCrossRefGoogle Scholar
  3. 3.
    Gottlieb JA, Baker LH, O’Bryan RM, et al.: Adriamycin used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep, Part 3 6:371–282, 1975.Google Scholar
  4. 4.
    Antman KH, Elias AD: Chemotherapy of advanced soft-tissue sarcomas. Semin Surg Oncol 4:53–58, 1988.PubMedCrossRefGoogle Scholar
  5. 5.
    Bramwell VHC, Mouridsen HT, Santoro A, et al.: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trail in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311–321, 1987.PubMedCrossRefGoogle Scholar
  6. 6.
    Samson MK, Baker LH, Benjamin RS, Lane M, Plager C: cis-Dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: A Southwest Oncology Group study. Cancer Treat Rep 63:2027–2029, 1979.PubMedGoogle Scholar
  7. 7.
    Karakousis CP, Holtermann OA, Holyoke ED: cis-Dichlorodiammineplatinum(II) in metastatic soft tissue sarcomas. Cancer Treat Rep 63:2071–2075, 1979.PubMedGoogle Scholar
  8. 8.
    Omura GA, Major FJ, Blessing JA, et al.: A randomized study of adriamycin with and without dimethyl trazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626–632, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    Lerner H, Amato D, Stevens C, Borden E, Enterline H: Leiomyosarcoma: The Eastern Cooperative Oncology group experience with 222 patients. Proc Am Assoc Cancer Res 24:142, 1983.Google Scholar
  10. 10.
    Elias A, Ryan L, Sulkes A, et al.: Response to mesna, doxrubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7:1208, 1989.PubMedGoogle Scholar
  11. 11.
    Pezzi CM, Pollock RE, Evans HL, et al.: Preoperative chemotherapy for soft tissue sarcoma of the extremities. Ann Surg 211:476–481, 1990.PubMedCrossRefGoogle Scholar
  12. 12.
    Santoro A, Rouesse J, Steward W, et al.: A randomized EORTC study in advanced soft tissue sarcomas (STS): ADM vs. ADM + IFX vs. CYVADIC. Proc Am Soc Clin Oncol 9:309, 1990.Google Scholar
  13. 13.
    Santoro A, Bonadonna G: Soft tissue and bone sarcomas. In: Pinedo HM, Longo DL, Chabner BA, eds. Cancer Chemotherapy and Biological Response Modifiers Annual 12. New York: Elsevier, 1991.Google Scholar
  14. 14.
    Huth J, Eilber FR: Patterns of metastatic spread following resection of extremity soft tissue sarcomas and strategies for treatment. Semin Surg Oncol 4:20–26, 1988.PubMedCrossRefGoogle Scholar
  15. 15.
    Rosen G, Caparros B, Huvos AG, et al.: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230, 1982.PubMedCrossRefGoogle Scholar
  16. 16.
    Huth JF, Mirra JJ, Eilber FR: Assessment of in vivo response to preoperative chemotherapy and radiation therapy as a predictor of survival in patients with soft tissue sarcoma. Am J Clin Oncol 8:497–503, 1985.PubMedCrossRefGoogle Scholar
  17. 17.
    Haskell CM, Silverstein MJ, Rangel DM, Hunt JS, Sparks FC, Morton DL: Multimodality cancer therapy in man: A pilot study of adriamycin by arterial infusion. Cancer 33:1485–1490, 1974.CrossRefGoogle Scholar
  18. 18.
    Eilber FR, Townsend CM, Weisenberger TH, et al.: A clinicopathologic study: Preoperative intraarterial adriamycin and radiation therapy for extremity soft tissue sarcomas. In: Management of Primary Soft Tissue Tumors: Proceedings of the Annual Clinical Conference on Cancer, MD Anderson Hospital. Chicago: Year Book Medical, 1977, pp 411–422.Google Scholar
  19. 19.
    Morton DL, Eilber FR, Townsend CM, Grant TT, Mirra J, Weisenburger TH: Limb salvage from a multidisciplinary treatment approach for skeletal and soft tissue sarcomas of the extremity. Ann Surg 184:268–278, 1976.PubMedCrossRefGoogle Scholar
  20. 20.
    Eilber FR, Guiliano AE, Huth J, Mirra J, Morton DL: Limb salvage for high grade soft tissue sarcomas of the extremity: Experience at the University of California, Los Angeles. Cancer Treat Symp 3:49–57, 1985.Google Scholar
  21. 21.
    Eilber FR, Mirra J, Eckardt J, Kern D: Intraarterial adriamycin, radiation therapy and surgical excision for extremity skeletal and soft tissue sarcomas. Dev Oncol 26:141–152, 1984.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • C. Jay Engel
  • Frederick R. Eilber
  • Gerald Rosen
  • Michael T. Selch
  • Yao-Shi Fu

There are no affiliations available

Personalised recommendations